40^th European Cardiology Conference

Cardiovascular pharmacology and drug development

Cardiovascular pharmacology and drug development are pivotal in advancing the treatment and management of heart and vascular diseases, which remain the leading causes ofmorbidity and mortality worldwide. This field focuses on understanding the mechanisms of action, efficacy, and safety of drugs targeting cardiovascular conditions such as hypertension, arrhythmias, heart failure, and atherosclerosis. Emerging therapies are addressing unmet needs with innovative approaches, including novel classes of antihypertensive, antithrombotic agents, and lipid-lowering drugs like PCSK9 inhibitors. Advances in biologics and gene-based therapies are opening new doors for treating genetic cardiovascular disorders and repairing damaged tissue. The incorporation of precision medicine is reshaping drug development by tailoring therapies to an individual’s genetic makeup, ensuring optimal efficacy and minimizing side effects. Nanotechnology is enhancing drug delivery systems, allowing for targeted delivery to specific tissues and improved bioavailability. High-throughput screening and AI-driven drug discovery are accelerating the development process, enabling the identification of promising compounds more efficiently. Clinical trials are also evolving, incorporating real-world data and biomarkers for better patient stratification and outcome measurement. By integrating cutting-edge research with patient-centric approaches, cardiovascular pharmacology continues to innovate, offering hope for improved outcomes and quality of life for patients worldwide.